Minerva Neurosciences, Inc. (NERV)Healthcare | Biotechnology | Burlington, United States | NasdaqCM
4.84 USD
-0.29
(-5.653%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 4.89 +0.05 (1.033%) ⇧ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 6 a.m. EDT
Minerva Neurosciences presents a classic distressed biotech profile where the market has priced out the business entirely due to a catastrophic multi-year decline. The stock has lost 97.66% of its value over the last nine years, with the trailing twelve months showing a sharp 6.18% drop. While the company recently secured a $200 million financing deal to advance its Roluperidone program—a necessary lifeline for survival—the balance sheet remains fragile with negative book value and significant operating cash burn. The recent price action shows a modest bounce off the lows, but the lack of institutional accumulation and the absence of meaningful options flow suggest the market views this as a high-risk turnaround play rather than a recovery vehicle. With no dividend to provide income and a statistical forecast leaning slightly negative despite the financing news, the investment case relies entirely on the successful execution of the Phase 3 trial, making it a speculative hold rather than a core position. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.088278 |
| AutoETS | 0.103796 |
| AutoTheta | 0.288884 |
| AutoARIMA | 0.396760 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 38% |
| H-stat | 0.88 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.376 |
| Excess Kurtosis | -0.69 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 231,098,192 |
| Forward P/E | -11.52 |
| Beta | -0.11 |
| Website | https://www.minervaneurosciences.com |
As of Aug. 22, 2026, 6 a.m. EDT: Options activity is virtually dormant with negligible open interest and volume across both calls and puts. Implied volatility is extremely low, indicating a lack of speculative positioning or anticipated catalyst-driven moves in the near term.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.2649007 |
| Address1 | 1,500 District Avenue |
| All Time High | 126.72 |
| All Time Low | 1.15 |
| Ask | 6.24 |
| Ask Size | 2 |
| Average Analyst Rating | 2.0 - Buy |
| Average Daily Volume10 Day | 376,890 |
| Average Daily Volume3 Month | 257,517 |
| Average Volume | 257,517 |
| Average Volume10Days | 376,890 |
| Beta | -0.109 |
| Bid | 4.87 |
| Bid Size | 1 |
| Book Value | -4.516 |
| City | Burlington |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.84 |
| Current Ratio | 20.144 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 5.3 |
| Day Low | 4.82 |
| Display Name | Minerva Neurosciences |
| Earnings Timestamp End | 1,754,397,000 |
| Earnings Timestamp Start | 1,754,397,000 |
| Ebitda | -28,534,206 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -7.975 |
| Enterprise Value | 227,572,256 |
| Eps Current Year | -0.57 |
| Eps Forward | -0.42 |
| Eps Trailing Twelve Months | -34.08 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.5015 |
| Fifty Day Average Change | 0.33850002 |
| Fifty Day Average Change Percent | 0.07519716 |
| Fifty Two Week Change Percent | 126.49007 |
| Fifty Two Week High | 12.46 |
| Fifty Two Week High Change | -7.62 |
| Fifty Two Week High Change Percent | -0.61155695 |
| Fifty Two Week Low | 1.93 |
| Fifty Two Week Low Change | 2.9100003 |
| Fifty Two Week Low Change Percent | 1.5077722 |
| Fifty Two Week Range | 1.93 - 12.46 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,404,221,400,000 |
| Float Shares | 34,299,936 |
| Forward Eps | -0.42 |
| Forward P E | -11.52381 |
| Free Cashflow | -8,862,641 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 7 |
| Fullday Change | -0.29 |
| Fullday Change Percent | -5.65302 |
| Fullday Price | 4.89 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -15,541,195 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03263 |
| Held Percent Institutions | 0.93291 |
| Implied Shares Outstanding | 47,747,559 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,655,769,600 |
| Last Split Factor | 1:8 |
| Long Business Summary | Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts. |
| Long Name | Minerva Neurosciences, Inc. |
| Market | us_market |
| Market Cap | 231,098,192 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_261133065 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -394,349,728 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 244,944,977 |
| Number Of Analyst Opinions | 3 |
| Open | 5.17 |
| Operating Cashflow | -26,168,724 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 617 600 7373 |
| Post Market Change | 0.049999714 |
| Post Market Change Percent | 1.0330518 |
| Post Market Price | 4.89 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 5.13 |
| Price Eps Current Year | -8.491228 |
| Price Hint | 4 |
| Price To Book | -1.071745 |
| Profit Margins | 0.0 |
| Quick Ratio | 19.016 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.0 |
| Region | US |
| Regular Market Change | -0.29 |
| Regular Market Change Percent | -5.65302 |
| Regular Market Day High | 5.3 |
| Regular Market Day Low | 4.82 |
| Regular Market Day Range | 4.82 - 5.3 |
| Regular Market Open | 5.17 |
| Regular Market Previous Close | 5.13 |
| Regular Market Price | 4.84 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 135,732 |
| Return On Assets | -0.28424 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 47,747,559 |
| Shares Percent Shares Out | 0.0368 |
| Shares Short | 1,755,972 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 2,420,231 |
| Short Name | Minerva Neurosciences, Inc |
| Short Percent Of Float | 0.0385 |
| Short Ratio | 11.14 |
| Source Interval | 15 |
| State | MA |
| Symbol | NERV |
| Target High Price | 14.0 |
| Target Low Price | 7.0 |
| Target Mean Price | 10.33333 |
| Target Median Price | 10.0 |
| Total Cash | 75,267,248 |
| Total Cash Per Share | 1.576 |
| Total Debt | 60,000,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -34.08 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 5.06065 |
| Two Hundred Day Average Change | -0.22064972 |
| Two Hundred Day Average Change Percent | -0.043601066 |
| Type Disp | Equity |
| Volume | 135,732 |
| Website | https://www.minervaneurosciences.com |
| Zip | 1,803 |